Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Topiramate; Carbamazepine; Valproate · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Topiramate; Carbamazepine; Valproate | DRUG | - |
Inclusion Criteria: * Body weight of at least 30 kilograms * New epilepsy diagnosis and at least one unprovoked seizure within 3 months before study entry * No history of antiepileptic drug use or taking a single antiepileptic drug for no longer than 6 weeks * Females must be sexually abstinent, su...
Top 9 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Xenon Pharmaceuticals Inc. | XENE | 4 | PHASE3 | Azetukalner |
| Praxis Precision Medicines, Inc. | PRAX | 5 | PHASE3 | Vormatrigine, Elsunersen |
| Rapport Therapeutics, Inc. | RAPP | 3 | PHASE3 | RAP-219 |
| Supernus Pharmaceuticals, Inc. | SUPN | 4 | PHASE2 | SPN-817, BIS-001ER |
| Biohaven Ltd. | BHVN | 3 | PHASE2 | BHV-7000 |
| Harmony Biosciences Holdings, Inc. | HRMY | 1 | PHASE3 | Clemizole |
| Jazz Pharmaceuticals Public Limited Company | JAZZ | 3 | PHASE1 | CBD-OS, Epidiolex |
| Bright Minds Biosciences Inc. | DRUG | 1 | PHASE2 | BMB-101 |
| uniQure N.V. | QURE | 1 | PHASE1 | AMT-260 |
Topiramate is an antiepileptic small molecule studied for the treatment of epilepsy and seizures. It has been evaluated as a treatment option for patients newly diagnosed with epilepsy, including a Phase 3 study comparing it with a standard therapy. It is used in epilepsy management alongside other antiepileptic agents such as carbamazepine and valproate.
Johnson & Johnson, which trades under the ticker JNJ, is the developer associated with the Phase 3 epilepsy program for topiramate. The company sponsored a study evaluating topiramate compared with a standard therapy in patients newly diagnosed with epilepsy.
Topiramate has been studied in Phase 3 clinical development for epilepsy. The program includes one completed Phase 3 trial, and no active trials are currently listed. The completed study was randomized and double blind, enrolling 865 patients aged 6 years and older.
The Phase 3 trial for topiramate in epilepsy is NCT00236717, titled A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy. It is completed, enrolled 865 participants, and included patients aged 6 years and older of all sexes.
No. Topiramate, carbamazepine, and valproate are distinct antiepileptic small molecules. They are separate treatments that have been used in epilepsy care, and topiramate has been studied in comparison with a standard therapy in patients newly diagnosed with epilepsy.